



May 5, 2009

MannKind to Present at the Canaccord Adams Diabetes and Obesity Conference

VALENCIA, Calif.--(BUSINESS WIRE)--May. 5, 2009-- **MannKind Corporation (Nasdaq: MNKD)**, focused on discovering, developing and commercializing treatments for diabetes and cancer, announced today that it will present at the Canaccord Adams Diabetes and Obesity Conference on Tuesday, May 12, 2009 at 8:20 AM (EDT) at the InterContinental Barclay Hotel in New York City.

Interested parties can access a link to the live webcast of the presentation from the News & Events section of the Company's website at <http://www.mannkindcorp.com>. Replays of the presentations will be available for 14 days.

About MannKind Corporation

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. Its diabetes pipeline includes AFRESA®, an ultra rapid-acting insulin and MKC253, an inhaled formulation of human GLP-1. MannKind also has two cancer immunotherapeutic products in clinical development. MannKind maintains a website at <http://www.mannkindcorp.com> to which the company regularly posts copies of its press releases as well as additional information. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Source: MannKind Corporation

MannKind Corporation
Matthew J. Pfeffer
Corporate Vice President and
Chief Financial Officer
661-775-5300
mpfeffer@mannkindcorp.com